Aimei Health Technology Co., Ltd - Ordinary Share

Capital is passively invested in short‑duration U.S. government securities inside the trust. Sponsor and target paid monthly extension fees in 2025 and 2026, most recently 34,330.96 dollars per month, via promissory notes that may convert into private units at 10 dollars each upon a merger.

This structure, together with 1,725,000 founder shares, 69,000 representative shares, private units, and 1/5‑share rights, creates substantial dilution upon de‑SPAC and misaligns incentives with long‑term compounding for public holders. Deferred underwriting fees of 690,000 dollars further burden a prospective transaction.